Subscribe
ftc-istock-530746621-rivernorthphotography
RiverNorthPhotography / iStockphoto.com
29 March 2017Americas

FTC hails M&A activity in ‘historic’ 2016

Last year was a historic one for the US Federal Trade Commission, according to its “ Annual Highlights” report, issued yesterday.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.
Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

More on this story

Americas
Abbott’s $25bn St. Jude acquisition would be anti-competitive, says FTC
24 February 2017   The Federal Trade Commission has found after a public comment period that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would probably be anti-competitive.
Americas
FTC orders biggest ever divestiture in Teva Allergan deal
16 September 2016   The US Federal Trade Commission has approved a final order that Teva’s acquisition of Allergan’s generic pharmaceutical business for $40.5 billion would be anticompetitive.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic